Myeloproliferative Disorder malady

Wikipedia: The myeloproliferative diseases (MPDs) or myeloproliferative neoplasms (MPNs) are a group of diseases of...⁴⁴ more...

MalaCards: Myeloproliferative Disorder, also known as chronic myeloproliferative disorder, is related to down syndrome and myeloproliferative disorder with eosinophilia. An important gene associated with Myeloproliferative Disorder is ZMYM2 (zinc finger, MYM-type 2), and among its related pathways are Immune response IL-3 activation and signaling pathway and Immune response_IL-3 activation and signaling pathway. The drug phenylbutyrate sodium and the compounds glucose and cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, liver and myeloid, and related mouse phenotypes are craniofacial and respiratory system.

myeloproliferative disorder 7 33 chronic myeloproliferative disorder 43

myeloproliferative disorders 32 myeloproliferative disease 43

Diseases related to myeloproliferative disorder by text searches and GeneDecks gene sharing:

(show top 50)    (show all 794)

id	Related Disease	Score	Top Affiliating Genes
1	down syndrome	35.4	RB1, BCL3, BCR, JAK2, CD7, MLL
2	myeloproliferative disorder with eosinophilia	33.2	BCR, IFNA2, PDGFRB
3	myelodysplastic syndrome	32.6	KIT, KITLG, RAP1A, RAN, MPL, MPO
4	eosinophilic myeloproliferative disorder	32.5	FGFR1, TP53BP1, PDGFRA, PDGFRB
5	essential thrombocythemia	32.4	MPL, JAK2, THPO
6	acute megakaryoblastic leukemia	32.3	MPO, CD36, MLL, IL11, IL3, PF4
7	myelofibrosis	32.0	JAK2, CD177, FGF2, HMGA2, THPO, EPO
8	acute myeloid leukemia	31.4	KIT, FLT3, NPM1, RUNX1
9	venous thrombosis	31.2	VWF, SELP, JAK2, F5, F2, F10
10	eosinophilia	31.0	CNTRL, ZMYM2, BCR, CISH, MPO, JAK2
11	megakaryoblastic leukemia	31.0	KIT, KITLG, VWF, SELP, MPL, MPO
12	mastocytosis	31.0	KIT, KITLG, BCL2, BCL2L1, MPO, JAK2
13	chronic myeloproliferative disease	30.9	VEGFA, B2M, MPL, MPO, JAK2, CD177
14	juvenile myelomonocytic leukemia	30.3	RASA2, JAK2, FLT3, INPP5D, HRAS, TP53
15	polycythemia vera	30.1	KIT, KITLG, VWF, SELP, BCL2L1, BCR
16	chronic neutrophilic leukemia	29.6	MLL, CSF2, CSF3, CSF3R
17	hypereosinophilic syndrome	29.5	KIT, IL3, PDGFRA, PDGFRB, WT1
18	thrombocytosis	29.5	KITLG, VWF, SELP, VEGFA, MPL, JAK2
19	lymphoblastic lymphoma	29.4	MPO, CD7, MLL, FLI1, FGFR1, TRB@
20	myelomonocytic leukemia	29.3	RB1, MYB, RASA2, RAN, MPO, JAK2
21	neurofibromatosis	29.1	RET, KIT, KITLG, VHL, RASA2, HRAS
22	chronic myelomonocytic leukemia	28.9	RB1, RAN, MPO, JAK2, FLT3, IL3
23	portal vein thrombosis	28.9	SELP, JAK2, IFNA1, IFNA2, F5, F2
24	pancytopenia	28.9	MPL, MLL, IL3, IFNG, WT1, THPO
25	hyperhomocysteinemia	28.8	VWF, SELP, ITGB3, FGF2, F5, F2
26	myeloid malignancy	28.7	KIT, MPL, JAK2, MLL, FLT3, ENG
27	hepatitis	28.6	SELP, IFNA1, IFNA2, F2, TIMP2, THPO
28	polycythemia	28.6	KIT, KITLG, VWF, SELP, VHL, VEGFA
29	thromboembolism	28.5	VWF, SELP, GP6, F5, F2, F10
30	thrombosis	28.3	VWF, SELP, VHL, VEGFA, AXL, MPL
31	acute lymphoblastic leukemia	27.1	KIT, KITLG, RB1, MYB, RAN, BCL2
32	chronic lymphocytic leukemia	26.0	REL, MYB, BCL2, BCL2L1, BCL3, BCR
33	twinning	24.3	SH2B1, VWF, VEGFA, KDR, BCR, LAMP2
34	chronic myeloid leukemia	23.8	KIT, KITLG, PCM1, RB1, SELP, VEGFA
35	myeloid leukemia	23.6	CNTRL, KIT, KITLG, VWF, PCM1, RB1
36	leukemia	22.5	SH2B3, REL, CNTRL, KIT, KITLG, VWF
37	homocysteine	22.5	VWF, SELP, VHL, VEGFA, CD36, ITGB3
38	hematopoiesis	22.2	SH2B3, KIT, KITLG, RB1, VEGFA, VAV1
39	acute leukemia	21.5	KIT, KITLG, VWF, PCM1, RB1, SELP
40	fibrosis	21.5	KIT, KITLG, VWF, SELP, VHL, VEGFA
41	cerebritis	21.4	KITLG, VWF, SELP, VHL, VEGFA, RAN
42	anemia	21.0	CNTRL, KIT, KITLG, VWF, RB1, SELP
43	noonan syndrome	20.2	KITLG, VWF, SELP, VEGFA, KDR, LAMP2
44	lymphoblastic leukemia	19.7	KIT, KITLG, VWF, RB1, SELP, VEGFA
45	lymphocytic leukemia	19.7	REL, KIT, KITLG, RB1, SELP, VHL
46	diabetes mellitus	19.3	SH2B3, RET, VWF, SELP, VEGFA, BCL2
47	sm-ahnmd	14.3	KIT, KITLG, JAK2, FGFR1, IFNA2, PDGFRA
48	dyserythropoietic anemia with thrombocytopenia	14.2	KITLG, MPL, IL11, IL3, IFNA1, THPO
49	diamond-blackfan anemia	14.2	KITLG, RAN, JAK2, IL3, G6PD, THPO
50	hemorrhagic thrombocythemia	14.2	MPL, JAK2, CD177, THPO

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 phenylbutyrate sodium

MalaCards organs/tissues related to myeloproliferative disorder:

²²

MGI Mouse Phenotypes related to myeloproliferative disorder:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	craniofacial phenotype	MP:0005382	10.3	KIT, KITLG, LAMP2, MN1, MLL, GRB2
2	respiratory system phenotype	MP:0005388	9.8	REL, RET, SELP, MN1, ITGB3, INPP5D
3	other phenotype	MP:0005395	9.7	SH2B3, KDR, JAK2, ITGB3, FN1, IL2
4	embryogenesis phenotype	MP:0005380	9.2	REL, RET, KIT, VHL, VAV1, MYB
5	hematopoietic system phenotype	MP:0005397	9.1	SH2B2, SH2B3, KIT, VHL, RAP1A, BCL2
6	renal/urinary system phenotype	MP:0005367	9.1	RET, KIT, SELP, VHL, BCL2, BCR
7	endocrine/exocrine gland phenotype	MP:0005379	9.0	SH2B1, RET, FGFR1, IL2, IFNG, CASP8
8	hearing/vestibular/ear phenotype	MP:0005377	8.7	KIT, KITLG, RB1, BCL2, BCR, MLL
9	normal phenotype	MP:0002873	8.4	RET, VHL, VEGFA, VBP1, VAV1, MYB
10	no phenotypic analysis	MP:0003012	8.3	RET, RB1, VEGFA, MLL, FGFR1, IGF2
11	adipose tissue phenotype	MP:0005375	8.2	RB1, BCL2, CD36, FECH, HMGA2, TP53
12	pigmentation phenotype	MP:0001186	8.2	KIT, KITLG, RB1, BCL2, MDM2, CASP3
13	limbs/digits/tail phenotype	MP:0005371	7.9	RET, KIT, KITLG, RB1, VHL, VEGFA
14	nervous system phenotype	MP:0003631	7.6	REL, KIT, KITLG, VWF, RB1, SELP
15	immune system phenotype	MP:0005387	7.4	SH2B1, REL, KIT, VWF, SELP, MYB
16	behavior/neurological phenotype	MP:0005386	7.4	KIT, RB1, SELP, RAP1A, KDR, BCR
17	integument phenotype	MP:0010771	6.9	REL, KIT, KITLG, RB1, SELP, VHL
18	skeleton phenotype	MP:0005390	6.9	REL, KIT, KITLG, RB1, VHL, VEGFA
19	reproductive system phenotype	MP:0005389	6.8	SH2B1, RET, VHL, VEGFA, VAV1, LAMP2
20	liver/biliary system phenotype	MP:0005370	6.7	REL, KIT, VHL, VEGFA, MYB, CD36
21	vision/eye phenotype	MP:0005391	6.2	KIT, KITLG, RB1, SELP, VEGFA, KDR
22	digestive/alimentary phenotype	MP:0005381	6.2	REL, RET, KIT, KITLG, VWF, RB1
23	mortality/aging	MP:0010768	5.6	SH2B1, REL, RET, KITLG, VWF, RB1
24	tumorigenesis	MP:0002006	5.4	RET, KIT, KITLG, RB1, VHL, BCL2
25	muscle phenotype	MP:0005369	5.4	RET, KIT, RB1, VHL, VEGFA, KDR
26	growth/size phenotype	MP:0005378	5.2	SH2B1, REL, RET, KIT, KITLG, RB1
27	cellular phenotype	MP:0005384	3.0	SH2B2, SH2B3, REL, RET, KIT, KITLG
28	cardiovascular system phenotype	MP:0005385	2.9	REL, RET, KIT, KITLG, VWF, RB1
29	homeostasis/metabolism phenotype	MP:0005376	2.4	SH2B1, SH2B2, REL, RET, KIT, KITLG

Articles related to myeloproliferative disorder:

(show top 50)    (show all 300)

id	Title	Authors	Year	Affiliating Genes
1	Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. (19135773)	Mercier F.... Galipeau J.	2009	JAK2
2	The impact of JAK2 non-receptor tyrosine kinase mutat ion on the mobilization of hematopoietic stem cells into peripheral blood of pa tients with Philadelphia chromosome-negative myeloproliferative disorders. (19462461)	Kannim S.... Auewarakul C.U.	2009	JAK2
3	New GATA1 mutation in codon 2 leads to the earliest k nown premature stop codon in transient myeloproliferative disorder. (19850750)	Hoeller S.... Bruder E.	2009	GATA1
4	Advance of study on JAK2 V617F in myeloproliferative disorders -- review (19236788)	Xu Y.Y.... Li H.M.	2009	ABL1
5	The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. (18521518)	Bellucci S.... Crassard I.	2008	JAK2
6	Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. (18566537)	Cross N.C.... Reiter A.	2008	FGFR1, PDGFRA, PDGFRB
7	Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. (18334677)	Xing S.... Zhao Z.J.	2008	THPO
8	Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. (19109573)	Zhao R.... Alexander D.R.	2008	JAK2
9	Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. (17440677)	Langabeer S.E.... Lawler M.	2007	JAK2
10	The genetic basis of myeloproliferative disorders. (18024602)	Skoda R.	2007	JAK2
11	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. (17384221)	Chen Q.... Wang Y.L.	2007	JAK2
12	The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. (17317861)	Hookham M.B.... Johnston J.A.	2007	JAK2, SOCS3
13	VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. (18024322)	Gianelli U.... Deliliers G.L.	2007	VEGFA
14	Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders. (16308183)	Emiliani C.... Gresele P.	2006	LAMP2
15	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. (16998940)	Rumi E.... Cazzola M.	2006	JAK2
16	Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. (16150949)	Goodwin R.G.... Elder G.H.	2006	FECH
17	Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. (16502590)	Campbell P.J.... Erber W.N.	2006	JAK2
18	Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. (16810616)	QuintA!s-Cardama A.... Verstovsek S.	2006	IFNA1
19	WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. (16242775)	Hasle H.... A9stergaard M.	2006	WT1
20	New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation (17032592)	Larsen T.S.... Hasselbalch H.C.	2006	JAK2
21	Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders (17145024)	Remacha A.F.... Canals C.	2006	JAK2
22	Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. (16645202)	Bock O.... Kreipe H.	2006	JAK2
23	Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. (16873677)	Campbell P.J.... Green A.R.	2006	JAK2
24	Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. (16998319)	Brink D.S.	2006	GATA1
25	Myeloproliferative disorders: the centrosome connection. (16107884)	Delaval B.... Birnbaum D.	2005	FGFR1
26	JAK2 mutations in myeloproliferative disorders. (16192494)	Tefferi A.... Gilliland G.	2005	JAK2
27	Identification of an acquired mutation in Jak2 provid es molecular insights into the pathogenesis of myeloproliferative disorders. (16123535)	Pesu M.... Silvennoinen O.	2005	JAK2
28	Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. (15726648)	Bock O.... Kreipe H.	2005	TGFB1, TNFRSF11B
29	GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. (15686466)	Carpenter E.... Vora A.	2005	GATA1
30	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. (15036941)	Pardanani A.... Tefferi A.	2004	PDGFRA, PDGFRB
31	The chronic myeloproliferative disorders: clonality and clinical heterogeneity. (15190515)	Spivak J.L.	2004	MPL
32	JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. (15507213)	Passegue E.... Weissman I.L.	2004	JUNB
33	The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders. (14617008)	Bock O.... Kreipe H.	2003	CD177
34	Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. (14636651)	Greene M.E.... Crispino J.D.	2003	GATA1
35	Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. (12486316)	Rameshwar P.... Chang V.T.	2003	FN1, TAC1
36	Thrombopoietin expression and plasma concentrations in chronic myeloproliferative disorders. (12526917)	Tefferi A.	2003	THPO
37	Myeloproliferative disorders. (11640868)	Bench A.J.... Green A.R.	2001	FGFR1
38	Transient myeloproliferative disorder and acute myelo id leukemia in Down syndrome. An immunophenotypic analysis. (11488066)	Karandikar N.J.... Kroft S.H.	2001	CD7
39	Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. (10741923)	SchAPffski P.... Hertenstein B.	2000	IFNA2
40	Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders. (10598372)	Kanavaros P.... Georgoulias V.	1999	MDM2, TP53
41	The value of the ultrastructural pattern of myeloperoxidase and platelet peroxidase in identification of two blastic cell types during transformation of a chronic myeloproliferative disorder. (14653450)	Moldoveanu E.... Halalau F.	1996	MPO
42	Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. (8562412)	Li Y.... Briere J.	1996	IL3, MPL
43	The effect of interleukin-4 with or without mast cell growth factor on peripheral blood granulocyte-macrophage colony-forming cells in healthy controls and in myeloproliferative disorders. (7538328)	Siitonen T.... Koistinen P.	1995	KITLG, IL3
44	c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. (8555071)	Nakata Y.... Satow Y.	1995	KITLG
45	Adenosine deaminase (ADA), 5'-nucleotidase (5'N) and purine nucleoside phosphorylase (PNP) in lympho- and myeloproliferative disorders (7746892)	Warzocha K.... Robak T.	1994	ADA
46	Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. (7512174)	Siitonen T.... Koistinen P.	1994	KIT
47	The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders. (8319785)	Kanfer E.J.... Barrett A.J.	1993	IFNA1
48	Transient myeloproliferative disorder in a Down's neonate with rearranged T-cell receptor beta gene and evidence of in vivo maturation demonstrated by dual-colour flow cytometric DNA ploidy analysis. (8412331)	Kwong Y.L.... Chan L.C.	1993	TRB@
49	Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. (1503083)	Friedenberg W.R.... David D.E.	1992	PLAT
50	The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. (1586743)	Soekarman D.... Grosveld G.	1992	DEK

Genes related to myeloproliferative disorder according to GeneCards:

(show top 50)    (show all 153)

id	Symbol	Description	Score	GeneCards Section Context
1	ZMYM2	zinc finger, MYM-type 2	11.1	Aliases & Descriptions, Publications
2	PDGFRB	platelet-derived growth factor receptor, beta polypeptide	11.1	Summaries, Publications
3	FGFR1	fibroblast growth factor receptor 1	11.1	Summaries, Publications
4	FGFR1OP	FGFR1 oncogene partner	11.1	Summaries, Publications
5	CNTRL	centriolin	11.1	Publications, Summaries
6	TET2	tet methylcytosine dioxygenase 2	11.1	Summaries
7	PDE4DIP	phosphodiesterase 4D interacting protein	11.1	Publications, Summaries
8	JAK2	Janus kinase 2	11.0	Publications
9	PDGFRA	platelet-derived growth factor receptor, alpha polypeptide	11.0	Publications
10	BCR	breakpoint cluster region	11.0	Publications
11	IFNA2	interferon, alpha 2	11.0	Publications
12	CD177	CD177 molecule	11.0	Publications
13	MPL	myeloproliferative leukemia virus oncogene	11.0	Publications
14	GATA1	GATA binding protein 1 (globin transcription factor 1)	11.0	Publications
15	THPO	thrombopoietin	11.0	Publications
16	SIPA1	signal-induced proliferation-associated 1	11.0
17	STAT5A	signal transducer and activator of transcription 5A	11.0	Publications
18	JUNB	jun B proto-oncogene	11.0	Publications
19	IRF8	interferon regulatory factor 8	11.0	Publications
20	H19	H19, imprinted maternally expressed transcript (non-protein coding)	11.0	Publications
21	TP53BP1	tumor protein p53 binding protein 1	11.0	Publications
22	SOCS1	suppressor of cytokine signaling 1	11.0	Publications
23	EPOR	erythropoietin receptor	11.0	Publications
24	INPP5D	inositol polyphosphate-5-phosphatase, 145kDa	11.0
25	CISH	cytokine inducible SH2-containing protein	11.0
26	IL18R1	interleukin 18 receptor 1	11.0	Publications
27	GP6	glycoprotein VI (platelet)	11.0
28	HMGA2	high mobility group AT-hook 2	11.0	Publications
29	ALOX12	arachidonate 12-lipoxygenase	11.0	Publications
30	RAN	RAN, member RAS oncogene family	11.0
31	AXL	AXL receptor tyrosine kinase	11.0
32	PPBP	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)	11.0	Publications
33	PF4	platelet factor 4	11.0	Publications
34	ABL1	c-abl oncogene 1, non-receptor tyrosine kinase	11.0	Publications
35	CSF3R	colony stimulating factor 3 receptor (granulocyte)	11.0	Publications
36	TYK2	tyrosine kinase 2	11.0
37	STAT5B	signal transducer and activator of transcription 5B	11.0
38	THBD	thrombomodulin	11.0	Publications
39	HPRT1	hypoxanthine phosphoribosyltransferase 1	11.0	Publications
40	VAV1	vav 1 guanine nucleotide exchange factor	11.0
41	TKT	transketolase	11.0	Publications
42	RAP1A	RAP1A, member of RAS oncogene family	11.0
43	KITLG	KIT ligand	11.0	Publications
44	MLL	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)	11.0	Publications
45	IFNA1	interferon, alpha 1	11.0	Publications
46	IL3	interleukin 3 (colony-stimulating factor, multiple)	11.0	Publications
47	IL11	interleukin 11	11.0
48	PTPN11	protein tyrosine phosphatase, non-receptor type 11	11.0	Publications
49	EPO	erythropoietin	11.0	Publications
50	ENG	endoglin	11.0

Pathways related to myeloproliferative disorder according to GeneDecks:

(show top 50)    (show all 265)

id	Pathway	Score	Top Affiliating Genes
1	Immune response IL-3 activation and signaling pathway10	10.7	CISH, JUNB, JAK2, INPP5D, GRB2, IL3
2	Immune response_IL-3 activation and signaling pathway41	10.7	CISH, JUNB, JAK2, INPP5D, GRB2, IL3
3	Breast Cancer Regulation by Stathmin136	10.6	AXL, FGF2, GRB2, CALM1, NTRK3, PPBP
4	Paxillin Interactions36	10.5	KIT, KITLG, KDR, AXL, ITGB3, FLT3
5	Tyrosine Kinases / Adaptors3	10.4	SH2B2, RET, KIT, KITLG, KDR, BCR
6	14-3-3 Induced Intracellular Signaling36	10.4	KITLG, AXL, FLT3, FGF2, GRB2, IL3
7	Hematopoietic cell lineage20	10.3	KIT, KITLG, CD36, CD9, CD7, ITGB3
8	Development Thrombopoetin signaling via JAK-STAT pathway10	10.3	BCL2L1, CISH, MPL, JAK2, PTPN11, STAT5A
9	Akt Signaling36	10.2	KIT, AXL, FLT3, FGFR1, IL11, IL18R1
10	Ras Pathway36	10.2	KIT, RAP1A, KDR, AXL, ITGB3, FLT3
11	Development_EPO-induced Jak-STAT pathway41	10.2	SH2B2, BCL2, BCL2L1, CISH, JAK2, GRB2
12	Development EPO-induced Jak-STAT pathway10	10.2	SH2B2, BCL2, BCL2L1, CISH, JAK2, GRB2
13	ILK Signaling36	10.1	KIT, KITLG, KDR, AXL, JUNB, ITGB3
14	Endothelin-1 Signaling Pathway36	10.0	KIT, AXL, FLT3, GRB2, IL11, IL2
15	Jak-STAT signaling pathway20	10.0	BCL2L1, CISH, MPL, JAK2, IL11, IL2
16	CREB Pathway36	9.9	KIT, KITLG, KDR, FGFR1, GRB2, IL2
17	PPAR Pathway36	9.9	KIT, KITLG, ITGB3, FGF2, FGFR1, GRB2
18	GPCR Pathway36	9.4	KIT, KITLG, RAP1A, KDR, AXL, FLT3
19	PTEN Pathway36	9.4	KIT, KITLG, KDR, FN1, FGF2, FGFR1
20	Renin-Angiotensin Pathway36	9.4	KIT, KITLG, KDR, JAK2, FGF2, FGFR1
21	p70S6K Signaling36	9.3	KIT, KITLG, KDR, JAK2, FGF2, FGFR1
22	NFAT in Immune Response36	9.2	KIT, KITLG, KDR, AXL, FLT3, FGF2
23	JNK Pathway36	9.2	KIT, KITLG, KDR, BCL2, AXL, FLT3
24	ERK Signaling36	9.2	KIT, KITLG, RAP1A, AXL, FN1, FLT3
25	Nanog in Mammalian ESC Pluripotency36	9.1	KIT, KITLG, KDR, AXL, FLT3, FGF2
26	Rac1 Pathway36	9.1	KITLG, KDR, ITGB3, FGF2, FGFR1, IL2
27	eNOS Signaling36	9.1	KIT, KITLG, AXL, FLT3, FGFR1, IL2
28	Intracellular Calcium Signaling36	9.1	KIT, KITLG, KDR, AXL, FLT3, FGF2
29	Antioxidant Action of Vitamin-C36	9.0	KIT, KITLG, KDR, BCL2, JAK2, FGF2
30	Telomerase Components in Cell Signaling36	9.0	KIT, KITLG, RB1, KDR, FGF2, FGFR1
31	Estrogen Pathway36	8.9	KIT, KITLG, KDR, BCL2, AXL, FLT3
32	Activation of PKA through GPCR36	8.9	KIT, KITLG, RAP1A, KDR, AXL, FLT3
33	Rho Family GTPases36	8.9	KIT, KITLG, KDR, BCL2, AXL, ITGB3
34	Phospholipase-C Pathway36	8.8	KIT, KITLG, RAP1A, KDR, ITGB3, FN1
35	Apoptotic Pathways in Synovial Fibroblasts36	8.8	KIT, KITLG, KDR, FGF2, FGFR1, IL2
36	PAK Pathway36	8.6	KIT, KITLG, KDR, BCL2, FGF2, FGFR1
37	Tec Kinases Signaling36	8.6	KITLG, VAV1, BCL2, JAK2, ITGB3, FGF2
38	MAPK Signaling36	8.6	KIT, KITLG, RAP1A, KDR, BCL2, AXL
39	Activation of cAMP-Dependent PKA36	8.6	KITLG, RAP1A, KDR, AXL, FLT3, FGFR1
40	DHA Signaling36	8.5	KIT, KITLG, KDR, BCL2, BCL2L1, FGF2
41	Cytokine-cytokine receptor interaction20	8.5	KIT, KITLG, VEGFA, KDR, MPL, FLT3
42	TGF-Beta Pathway36	8.5	KITLG, KDR, BCL2, FGF2, FGFR1, GRB2
43	JAK-STAT Pathway36	8.3	KIT, KITLG, RAN, KDR, BCL2, AXL
44	p38 Signaling36	8.3	KIT, KITLG, KDR, BCL2, AXL, JUNB
45	Pancreatic Adenocarcinoma36	7.9	KIT, KITLG, RB1, KDR, BCL2, BCL2L1
46	p53 Mediated Apoptosis36	7.9	KIT, KITLG, KDR, BCL2, FGF2, FGFR1
47	Mitochondrial Apoptosis36	7.7	KIT, KITLG, KDR, BCL2, BCL2L1, FGF2
48	Cellular Apoptosis Pathway36	7.6	KIT, KITLG, KDR, BCL2, BCL2L1, FGF2
49	Pathways in cancer20	7.3	RET, RB1, VEGFA, BCL2, BCL2L1, BCR
50	Molecular Mechanisms of Cancer36	6.6	KITLG, RB1, RAP1A, KDR, BCL2, BCL2L1

Compounds related to myeloproliferative disorder according to GeneDecks:

(show top 50)    (show all 456)

id	Compound	Score	Top Affiliating Genes
1	glucose32	10.8	KIT, VHL, CISH, JUNB, FGFR1, IL11
2	cyclophosphamide32 34 9 9	13.8	TRB@, TAC1
3	vincristine32 34 9 9	13.5	KIT, MLL, FGF2, IFNA1, CSF2, ADA
4	lysine32	10.5	REL, MYB, CISH, MPL, TP53BP1, TNFRSF11B
5	threonine32	10.2	SH2B1, REL, RET, RAP1A, MPL, MLL
6	phosphotyrosine32	10.0	SH2B2, SH2B3, RET, KIT, VAV1, RASA2
7	agar32	10.0	RET, KITLG, RB1, RAP1A, JAK2, FN1
8	methylcellulose32	9.9	KIT, KITLG, VAV1, MYB, FLT3, FGF2
9	ascorbic acid32 18	10.9	JAK2, CD36, CD9, IL3, ENG, IGF2
10	pge232	9.7	RAP1A, JUNB, FN1, FGF2, ALOX12, TNFRSF11B
11	creatinine32	9.5	KITLG, VWF, SELP, B2M, MPO, FN1
12	superoxide32 18	10.5	KITLG, RB1, VAV1, RAP1A, RAN, MPO
13	progesterone32 42 9 18 9	13.5	KIT, RB1, MYB, BCL2, FGFR1, ENG
14	phosphatidylserine32 9 9	11.4	VWF, BCL2, AXL, MCL1, GP6, F5
15	calcitriol32 42 9 18 9	13.2	KITLG, RB1, B2M, JUNB, CD36, MLL
16	oxygen32 18	10.2	KITLG, RB1, MYB, RAP1A, RAN, BCL2
17	estrogen32	9.1	VWF, VHL, KDR, CISH, CD36, ITGB3
18	lipid32	9.0	RET, KITLG, RB1, VAV1, MYB, RAP1A
19	adenylate32	8.9	KITLG, VWF, SELP, MYB, RAP1A, FGFR1
20	12-o-tetradecanoylphorbol 13-acetate32	8.8	RET, RB1, RAP1A, JUNB, JAK2, CD9
21	atp32	8.8	RET, KIT, RB1, RAN, BCL2L1, BCR
22	n acetylcysteine32	8.7	VWF, SELP, KDR, JAK2, GRB2, IL3
23	daunorubicin32 9 9	10.6	KITLG, BCL2, BCL2L1, MPO, CD36, FLT3
24	wortmannin32 42	9.5	RET, KITLG, VAV1, KDR, BCL2, BCL2L1
25	agarose32	8.5	KIT, KITLG, VWF, BCL2, BCL2L1, FLT3
26	nitric oxide32 9 18 9	11.4	REL, KIT, KITLG, RB1, SELP, VHL
27	lactate32	8.4	KIT, KITLG, VWF, SELP, KDR, B2M
28	cytarabine32 34 9 9	11.4	KIT, KITLG, RB1, BCL2, BCL2L1, BCR
29	matrigel32	8.3	VWF, RB1, VEGFA, KDR, BCL2L1, JAK2
30	adp32 18	9.2	RET, KIT, VWF, SELP, KDR, BCL2L1
31	glutamine32	8.1	KIT, VWF, MYB, RAP1A, B2M, CD36
32	cysteine32	8.0	REL, SELP, MYB, RAN, KDR, BCL2L1
33	thalidomide32 42 9 9	10.8	VEGFA, KDR, BCL2L1, B2M, CD36, FGF2
34	pd 98,05932	7.8	RET, KIT, KITLG, RB1, BCL2, BCL2L1
35	calcium32 9 18 9	10.8	REL, KIT, KITLG, VWF, RB1, VHL
36	gm-csf32	7.8	KITLG, VEGFA, BCL2L1, IL11, IL2, IL3
37	thapsigargin32 42	8.6	MYB, BCL2, BCL2L1, BCR, CISH, CD36
38	thymidine32 18	8.6	KIT, KITLG, RB1, MYB, KDR, BCR
39	arsenite32 18	8.5	VEGFA, BCL2, BCL2L1, JAK2, FLT3, MDM2
40	adriamycin32	7.4	RB1, BCL2, BCL2L1, B2M, CD36, FN1
41	sb 20358032 42	8.2	RB1, VEGFA, BCL2, BCL2L1, JUNB, CD36
42	tamoxifen32 34 9 9	10.0	VEGFA, KDR, BCL2, JUNB, GRB2, IL2
43	curcumin32	6.9	VEGFA, BCL2, BCL2L1, JAK2, MDM2, MCL1
44	retinoic acid32 42 18	8.2	REL, RET, KIT, KITLG, VWF, RB1
45	butyrate32	6.2	RET, KITLG, RB1, MYB, BCL2, BCL2L1
46	5fluorouracil32	6.0	KIT, KITLG, RB1, VEGFA, KDR, BCL2
47	paraffin32	5.8	RET, KIT, KITLG, VWF, RB1, VEGFA
48	cisplatin32 34 9 9	8.3	KITLG, RB1, VEGFA, RAN, KDR, BCL2
49	genistein32 9 18 9	7.9	RET, KITLG, RB1, SELP, VEGFA, KDR
50	actinomycin d32	4.5	KIT, KITLG, RB1, VHL, VEGFA, MYB

Cellular components related to myeloproliferative disorder according to GeneDecks:

(show all 12)

id	Name	GO ID	Score	Top Affiliating Genes
1	platelet alpha granule membrane	GO:031092	10.2	ITGB3, CD36, CD9, SELP
2	centrosome	GO:005813	9.3	PCM1, CNTRL, BCL2L1, CEP350, FGFR1OP, KIF20B
3	external side of plasma membrane	GO:009897	9.1	ADA, TLR4, PTPRC, IFNG, ANPEP, ENG
4	integral to plasma membrane	GO:005887	9.1	KDR, NTRK3, PTPRC, TNFSF10, ANPEP, GP6
5	platelet alpha granule lumen	GO:031093	9.0	F5, PPBP, PF4, TIMP1, FN1, VEGFA
6	nucleoplasm	GO:005654	8.5	KIF20B, STAT5A, RB1, RAN, JUNB, MDM2
7	membrane	GO:016020	8.0	TYK2, VHL, ADA, SIPA1, VEGFA, BCL2
8	nucleus	GO:005634	7.4	FGF2, FLI1, IRF8, MLL, JAK2, FGFR1
9	cytosol	GO:005829	7.3	PTK2B, TP53, HPRT1, HRAS, CASP8, CASP3
10	extracellular space	GO:005615	7.2	IFNG, CSF3, ADA, EPO, CSF2, TAC1
11	extracellular region	GO:005576	6.5	KITLG, EPOR, PLAT, PPBP, TNFRSF11B, F10
12	cytoplasm	GO:005737	5.4	PDGFRB, PDGFRA, PDE4DIP, RNF6, NFKB2, NF1

Biological processes related to myeloproliferative disorder according to GeneDecks:

(show top 50)    (show all 85)

id	Name	GO ID	Score	Top Affiliating Genes
1	peptidyl-tyrosine phosphorylation	GO:018108	11.0	STAT5A, ABL2, ABL1, PDGFRB, PDGFRA, PTK2B
2	positive regulation of phospholipase C activity	GO:010863	11.0	PDGFRA, PDGFRB, FGFR1, FGF2, KIT
3	JAK-STAT cascade involved in growth hormone signaling pathway	GO:060397	10.9	STAT5A, SOCS1, SOCS2, STAT5B, JAK2, CISH
4	embryonic hemopoiesis	GO:035162	10.9	MLL, SH2B3, KIT, KITLG, KDR, GATA1
5	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	10.9	F2, PDGFRB, PDGFRA, FGFR1, FLT3, JAK2
6	JAK-STAT cascade	GO:007259	10.8	SOCS3, SOCS2, SOCS1, STAT5B, STAT5A, JAK2
7	positive regulation of DNA replication	GO:045740	10.8	EPO, KITLG, IL3, HRAS, PDGFRA, CSF2
8	dendritic cell differentiation	GO:097028	10.8	AXL, CSF2, FLT3, GATA1
9	leukocyte migration	GO:050900	10.7	F2, HRAS, PTPN11, THBD, GRB2, GP6
10	positive regulation of phosphatidylinositol 3-kinase activity	GO:043552	10.7	PDGFRA, PTK2B, FGF2, TGFB1, KIT, FLT3
11	regulation of actin cytoskeleton reorganization	GO:2000249	10.7	PTK2B, PDGFRA, ABL1, ABL2
12	regulation of cell adhesion	GO:030155	10.5	RET, ENG, PTK2B, ABL1, ABL2, STAT5A
13	cytokine-mediated signaling pathway	GO:019221	10.5	B2M, IFNA2, CSF3, SOCS1, STAT5B, STAT5A
14	regulation of interferon-gamma-mediated signaling pathway	GO:060334	10.4	JAK2, IFNG, PTPN11, SOCS3, SOCS1
15	response to lipopolysaccharide	GO:032496	10.3	SOCS3, EPO, TLR4, STAT5B, TAC1, THPO
16	positive regulation of MAPK cascade	GO:043410	10.3	IL11, KIT, CD36, FLT3, FGFR1, PTPRC
17	positive regulation of tyrosine phosphorylation of Stat5 protein	GO:042523	10.3	CSF2, KIT, EPO, JAK2, IL3, IL2
18	interferon-gamma-mediated signaling pathway	GO:060333	10.2	SOCS3, SOCS1, PTPN11, IRF8, JAK2, B2M
19	T cell homeostasis	GO:043029	10.1	BCL2, CASP3, TGFB1, STAT5A, STAT5B
20	response to progesterone stimulus	GO:032570	10.0	JUNB, SOCS3, TLR4, TGFB1, SOCS1
21	signal transduction	GO:007165	9.9	DEK, PRKG1, PRKG2, CSF3R, SIPA1, EPO
22	vascular endothelial growth factor receptor signaling pathway	GO:048010	9.8	KDR, PDGFRB, PDGFRA, PTK2B, VEGFA
23	T cell differentiation in thymus	GO:033077	9.8	B2M, BCL2, STAT5A, STAT5B, TP53
24	positive regulation of MAP kinase activity	GO:043406	9.7	VEGFA, FLT3, FGFR1, KITLG, PDGFRB, TGFB1
25	positive regulation of reactive oxygen species metabolic process	GO:2000379	9.7	TP53, F2, GRB2, CD36, PDGFRB
26	immune response	GO:006955	9.6	CD7, TNFSF10, TLR4, PF4, PPBP, IL7R
27	cell surface receptor signaling pathway	GO:007166	9.5	F2, PTPRC, CD36, IL7R, MPL, PTK2B
28	response to estradiol stimulus	GO:032355	9.5	SOCS3, STAT5B, SOCS1, SOCS2, CTNNB1, CASP8
29	response to ethanol	GO:045471	9.5	EP300, STAT5A, STAT5B, TLR4, BCL2, FECH
30	positive regulation of cell migration	GO:030335	9.5	RET, VEGFA, KDR, JAK2, FGFR1OP, F10
31	negative regulation of cell proliferation	GO:008285	9.2	TP53, NPM1, VHL, JAK2, CD9, TGFB1
32	positive regulation of protein phosphorylation	GO:001934	9.2	TGFB1, VEGFA, ITGB3, ENG, IGF2, HRAS
33	cell adhesion	GO:007155	9.2	KITLG, SELP, IL2, FN1, CD36, CD9
34	response to cytokine stimulus	GO:034097	9.1	TIMP1, MCL1, JUNB, BCL2L1, BCL2, CTNNB1
35	virus-host interaction	GO:019048	9.1	RB1, CASP8, ANPEP, MDM2, GRB2, ITGB3
36	positive regulation of apoptotic process	GO:043065	9.1	TP53, HMGA2, ALOX12, INPP5D, JAK2, TNFSF10
37	anti-apoptosis	GO:006916	9.1	BCL2L1, IL2, MPO, BCL2, VHL, MCL1
38	response to drug	GO:042493	9.1	TNFRSF11B, EP300, TGFB1, CREB1, CTNNB1, IFNG
39	positive regulation of transcription, DNA-dependent	GO:045893	9.0	VHL, TGFB1, WT1, RNF6, RAN, BCL3
40	induction of apoptosis by intracellular signals	GO:008629	9.0	BCL2L1, CASP8, TP53, CASP3, BCL2, HRAS
41	platelet degranulation	GO:002576	8.9	TIMP1, PPBP, PF4, TGFB1, F5, FN1
42	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	8.9	IGF2, TP53, PTK2B, TLR4, IL3, IL11
43	platelet activation	GO:030168	8.8	TGFB1, THPO, TIMP1, PF4, PPBP, F2
44	response to hypoxia	GO:001666	8.6	BCL2, ENG, VEGFA, PLAT, NF1, TLR4
45	negative regulation of transcription from RNA polymerase II promoter	GO:000122	8.5	NFIB, WT1, TGFB1, EP300, HDAC3, TP53
46	apoptotic process	GO:006915	8.2	CASP8, EPO, ABL1, CTNNB1, PTK2B, TNFSF10
47	negative regulation of apoptotic process	GO:043066	8.2	VEGFA, BCL2, EPO, BCL2L1, KDR, BCL3
48	positive regulation of cell proliferation	GO:008284	8.1	EPO, PTK2B, HRAS, ALOX12, F2, JAK2
49	blood coagulation	GO:007596	7.8	TIMP1, FN1, ITGB3, CD9, INPP5D, GRB2
50	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.1	MLL, FGF2, IL11, ENG, JUNB, MYB

Molecular functions related to myeloproliferative disorder according to GeneDecks:

(show all 17)

id	Name	GO ID	Score	Top Affiliating Genes
1	vascular endothelial growth factor-activated receptor activity	GO:005021	10.8	KDR, FLT3, PDGFRA, PDGFRB
2	vascular endothelial growth factor binding	GO:038085	10.7	PDGFRB, PDGFRA, KDR
3	protein tyrosine kinase activity	GO:004713	10.6	KIT, KDR, BCR, JAK2, FGFR1OP, PTK2B
4	growth hormone receptor binding	GO:005131	10.5	SOCS2, TYK2, JAK2
5	transmembrane receptor protein tyrosine kinase activity	GO:004714	10.5	PDGFRA, RET, KIT, KDR, AXL, FLT3
6	non-membrane spanning protein tyrosine kinase activity	GO:004715	10.4	JAK2, PTK2B, ABL1, ABL2, TYK2
7	receptor activity	GO:004872	9.9	TLR4, ANPEP, THBD, RET, CD7, ITGB3
8	BH3 domain binding	GO:051434	9.8	MCL1, BCL2L1, BCL2
9	platelet-derived growth factor receptor binding	GO:005161	9.8	ITGB3, VEGFA, PDGFRA, PDGFRB
10	heparin binding	GO:008201	9.6	SELP, VEGFA, MPO, FN1, FGFR1, PTPRC
11	androgen receptor binding	GO:050681	9.6	EP300, RNF6, RB1, RAN, CTNNB1
12	protein homodimerization activity	GO:042803	9.3	MLL, BCL2, RUNX1, TGFB1, FGFR1OP, VEGFA
13	transcription factor binding	GO:008134	9.0	HMGA2, TP53, CTNNB1, RUNX1, HDAC3, EP300
14	identical protein binding	GO:042802	8.8	MDM2, ITGB3, BCL2, PCM1, BCL2L1, MLL
15	growth factor activity	GO:008083	8.7	F2, THPO, TGFB1, CSF2, VEGFA, IGF2
16	cytokine activity	GO:005125	8.6	IFNA2, TNFSF10, THPO, IL2, CSF2, CSF3
17	protein binding	GO:005515	3.7	BCL2, MDM2, MCL1, ENG, GP6, IGF2